Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Innate Pharma (IPHA) FCF Margin (2020 - 2024)

Historic FCF Margin for Innate Pharma (IPHA) over the last 5 years, with Q4 2024 value amounting to 83.15%.

  • Innate Pharma's FCF Margin fell 204200.0% to 83.15% in Q4 2024 from the same period last year, while for Jun 2025 it was 53.79%, marking a year-over-year decrease of 201500.0%. This contributed to the annual value of 36.22% for FY2024, which is 171700.0% up from last year.
  • As of Q4 2024, Innate Pharma's FCF Margin stood at 83.15%, which was down 204200.0% from 62.73% recorded in Q4 2023.
  • Innate Pharma's FCF Margin's 5-year high stood at 38.63% during Q4 2022, with a 5-year trough of 482.64% in Q4 2021.
  • Moreover, its 5-year median value for FCF Margin was 83.15% (2024), whereas its average is 151.87%.
  • As far as peak fluctuations go, Innate Pharma's FCF Margin tumbled by -3904500bps in 2021, and later soared by 4440000bps in 2022.
  • Quarter analysis of 5 years shows Innate Pharma's FCF Margin stood at 92.19% in 2020, then plummeted by -424bps to 482.64% in 2021, then soared by 92bps to 38.63% in 2022, then crashed by -62bps to 62.73% in 2023, then plummeted by -33bps to 83.15% in 2024.
  • Its FCF Margin stands at 83.15% for Q4 2024, versus 62.73% for Q4 2023 and 38.63% for Q4 2022.